Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Opposing transcriptional programs of KLF5 and AR emerge during therapy for advanced prostate cancer.
Che M, Chaturvedi A, Munro SA, Pitzen SP, Ling A, Zhang W, Mentzer J, Ku SY, Puca L, Zhu Y, Bergman AM, Severson TM, Forster C, Liu Y, Hildebrand J, Daniel M, Wang TY, Selth LA, Hickey T, Zoubeidi A, Gleave M, Bareja R, Sboner A, Tilley W, Carroll JS, Tan W, Kohli M, Yang R, Hsieh AC, Murugan P, Zwart W, Beltran H, Huang RS, Dehm SM. Che M, et al. Among authors: ku sy. Nat Commun. 2021 Nov 4;12(1):6377. doi: 10.1038/s41467-021-26612-1. Nat Commun. 2021. PMID: 34737261 Free PMC article.
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.
Mu P, Zhang Z, Benelli M, Karthaus WR, Hoover E, Chen CC, Wongvipat J, Ku SY, Gao D, Cao Z, Shah N, Adams EJ, Abida W, Watson PA, Prandi D, Huang CH, de Stanchina E, Lowe SW, Ellis L, Beltran H, Rubin MA, Goodrich DW, Demichelis F, Sawyers CL. Mu P, et al. Among authors: ku sy. Science. 2017 Jan 6;355(6320):84-88. doi: 10.1126/science.aah4307. Science. 2017. PMID: 28059768 Free PMC article.
Towards precision oncology in advanced prostate cancer.
Ku SY, Gleave ME, Beltran H. Ku SY, et al. Nat Rev Urol. 2019 Nov;16(11):645-654. doi: 10.1038/s41585-019-0237-8. Epub 2019 Oct 7. Nat Rev Urol. 2019. PMID: 31591549 Free PMC article. Review.
Genomic and clinical characterization of stromal infiltration markers in prostate cancer.
Mahal BA, Alshalalfa M, Zhao SG, Beltran H, Chen WS, Chipidza F, Davicioni E, Karnes RJ, Ku SY, Lotan TL, Muralidhar V, Rebbeck TR, Schaeffer EM, Spratt DE, Feng FY, Nguyen PL. Mahal BA, et al. Among authors: ku sy. Cancer. 2020 Apr 1;126(7):1407-1412. doi: 10.1002/cncr.32688. Epub 2020 Jan 6. Cancer. 2020. PMID: 31905251 Free PMC article.
Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, Orlando F, Fedrizzi T, Ku SY, Dann E, Alonso A, Mosquera JM, Sboner A, Xiang J, Elemento O, Nanus DM, Tagawa ST, Benelli M, Demichelis F. Beltran H, et al. Among authors: ku sy. J Clin Invest. 2020 Apr 1;130(4):1653-1668. doi: 10.1172/JCI131041. J Clin Invest. 2020. PMID: 32091413 Free PMC article. Clinical Trial.
SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy.
Conteduca V, Ku SY, Puca L, Slade M, Fernandez L, Hess J, Bareja R, Vlachostergios PJ, Sigouros M, Mosquera JM, Sboner A, Nanus DM, Elemento O, Dittamore R, Tagawa ST, Beltran H. Conteduca V, et al. Among authors: ku sy. Mol Cancer Ther. 2020 May;19(5):1157-1164. doi: 10.1158/1535-7163.MCT-19-0926. Epub 2020 Mar 3. Mol Cancer Ther. 2020. PMID: 32127465 Free PMC article.
Transcriptional mediators of treatment resistance in lethal prostate cancer.
He MX, Cuoco MS, Crowdis J, Bosma-Moody A, Zhang Z, Bi K, Kanodia A, Su MJ, Ku SY, Garcia MM, Sweet AR, Rodman C, DelloStritto L, Silver R, Steinharter J, Shah P, Izar B, Walk NC, Burke KP, Bakouny Z, Tewari AK, Liu D, Camp SY, Vokes NI, Salari K, Park J, Vigneau S, Fong L, Russo JW, Yuan X, Balk SP, Beltran H, Rozenblatt-Rosen O, Regev A, Rotem A, Taplin ME, Van Allen EM. He MX, et al. Among authors: ku sy. Nat Med. 2021 Mar;27(3):426-433. doi: 10.1038/s41591-021-01244-6. Epub 2021 Mar 4. Nat Med. 2021. PMID: 33664492 Free PMC article.
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer.
Baca SC, Takeda DY, Seo JH, Hwang J, Ku SY, Arafeh R, Arnoff T, Agarwal S, Bell C, O'Connor E, Qiu X, Alaiwi SA, Corona RI, Fonseca MAS, Giambartolomei C, Cejas P, Lim K, He M, Sheahan A, Nassar A, Berchuck JE, Brown L, Nguyen HM, Coleman IM, Kaipainen A, De Sarkar N, Nelson PS, Morrissey C, Korthauer K, Pomerantz MM, Ellis L, Pasaniuc B, Lawrenson K, Kelly K, Zoubeidi A, Hahn WC, Beltran H, Long HW, Brown M, Corey E, Freedman ML. Baca SC, et al. Among authors: ku sy. Nat Commun. 2021 Mar 30;12(1):1979. doi: 10.1038/s41467-021-22139-7. Nat Commun. 2021. PMID: 33785741 Free PMC article.
Epigenetics in prostate cancer: clinical implications.
Conteduca V, Hess J, Yamada Y, Ku SY, Beltran H. Conteduca V, et al. Among authors: ku sy. Transl Androl Urol. 2021 Jul;10(7):3104-3116. doi: 10.21037/tau-20-1339. Transl Androl Urol. 2021. PMID: 34430414 Free PMC article. Review.
233 results